榴莲视频

A look back at some of the newsworthy developments of 2024

Largest survival benefit observed in patients who entered a cessation program within 6 months

Debate highlights pros and cons of the new recommendation

Osimertinib plus ramucirumab in first line shows 9-month PFS advantage over EGFR inhibition alone

Study raises questions about how to assess patient risk, experts say

Latest negative results emphasize "critical" aspect of immunotherapy timing

EGFR inhibitor now indicated for unresectable stage III disease following chemoradiotherapy

Actual rates for 2021 lagged behind projections

Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan

However, plinabulin plus docetaxel still "not ready for prime time," expert says

Absolute improvement of almost 30%, doubling of duration of response with savolitinib

Two-trial analysis shows about a 40% decreased risk of disease recurrence or death

Novel agent nearly halved risk of progression as first-line therapy in phase III trial

Add-on ADC, monoclonal antibody consistently increase pCR versus PD-1 inhibitor plus chemotherapy